Buruli ulcer: Advances in understanding mycobacterium ulcerans infection

Dermatologic Clinics

Volumn 29, Issue 1, 2011, Pages 1-8

  Walsh, Douglas S ^a   Portaels, Françoise ^b   Meyers, Wayne M ^c  

^a U S ARMY   (United States)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

Author keywords

Buruli ulcer; Emerging disease; Mycobacterium ulcerans; Mycolactone; Skin disease

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; BCG VACCINE; CLARITHROMYCIN; GAMMA INTERFERON; INTERLEUKIN 10; MOXIFLOXACIN; RIFAMPICIN; RIFAPENTINE; STREPTOMYCIN;

ADJUVANT THERAPY; BACTERIAL GENE; BACTERIAL IMMUNITY; BACTERIAL TRANSMISSION; BURULI ULCER; CLINICAL FEATURE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE SEVERITY; GEOGRAPHIC DISTRIBUTION; HUMAN; INFECTION RISK; MYCOBACTERIUM ULCERANS; NONHUMAN; OSTEOMYELITIS; PATHOGENESIS; PHYSIOTHERAPY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; REVIEW; SEASONAL VARIATION; SERODIAGNOSIS; VACCINE PRODUCTION;

BURULI ULCER; HUMANS; MYCOBACTERIUM INFECTIONS, ATYPICAL; MYCOBACTERIUM ULCERANS;

EID: 78649371763     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.det.2010.09.006     Document Type: Review

References (52)

1. Silva M.T., Portaels F., Pedrosa J. Pathogenetic mechanisms of the intracellular parasite Mycobacterium ulcerans leading to Buruli ulcer. Lancet Infect Dis 2009, 9:699-710.
2. World Health Organization Buruli ulcer progress report, 2004-2008. Wkly Epidemiol Rec 2008, 83:145-154.
3. Walsh D.S., Eyase F., Onyango D., et al. Short report: clinical and molecular evidence for a case of Buruli ulcer (Mycobacterium ulcerans infection) in Kenya. Am J Trop Med Hyg 2009, 81:1110-1113.
4. Barogui Y., Johnson R.C., van der Werf T.S., et al. Functional limitations after surgical or antibiotic treatment for Buruli ulcer in Benin. Am J Trop Med Hyg 2009, 81:82-87.
5. McGann H., Stragier P., Portaels F., et al. Buruli ulcer in United Kingdom tourist returning from Latin America. Emerg Infect Dis 2009, 15:1827-1829.
6. Portaels F., Silva M.T., Meyers W.M. Buruli ulcer. Clin Dermatol 2009, 27:291-305.
7. Marion E., Eyangoh S., Yeramian E., et al. Seasonal and regional dynamics of M. ulcerans transmission in environmental context: deciphering the role of water bugs as hosts and vectors. PLoS Negl Trop Dis 2010, 4:e731.
8. Johnson P.D., Lavender C.J. Correlation between Buruli ulcer and vector-borne notifiable diseases, Victoria, Australia. Emerg Infect Dis 2009, 15:614-615.
9. Durnez L., Suykerbuyk P., Nicolas V., et al. The role of terrestrial small mammals as reservoir of Mycobacterium ulcerans in Benin. Appl Environ Microbiol 2010, 76:4574-4577.
10. Jacobsen K.H., Padgett J.J. Risk factors for Mycobacterium ulcerans infection. Int J Infect Dis 2010, 14:e677-e681.
11. Sopoh G.E., Barogui Y.T., Johnson R.C., et al. Family relationship, water contact and occurrence of Buruli ulcer in Benin. PLoS Negl Trop Dis 2010, 4:e746.
12. Johnson R.C., Nackers F., Glynn J.R., et al. Association of HIV infection and Mycobacterium ulcerans disease in Benin. AIDS 2008, 22:901-903.
13. Portaels F., Aguiar J., Debacker M., et al. Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease. Infect Immun 2004, 72:62-65.
14. Smith P.G., Revill W.D., Lukwago E., et al. The protective effect of BCG against Mycobacterium ulcerans disease: a controlled trial in an endemic area of Uganda. Trans R Soc Trop Med Hyg 1977, 70:449-457.
15. Portaels F., Aguiar J., Debacker M., et al. Prophylactic effect of Mycobacterium bovis BCG vaccination against osteomyelitis in children with Mycobacterium ulcerans disease (Buruli ulcer). Clin Diagn Lab Immunol 2002, 9:1389-1391.
16. Nackers F., Dramaix M., Johnson R.C., et al. BCG vaccine effectiveness against Buruli ulcer: a case-control study in Benin. Am J Trop Med Hyg 2006, 75:768-774.
17. Huygen K., Adjei O., Affolabi D., et al. Buruli ulcer disease: prospects for a vaccine. Med Microbiol Immunol 2009, 198:69-77.
18. Vandelannoote K., Durnez L., Amissah D., et al. Application of real-time PCR in Ghana, a Buruli ulcer-endemic country, confirms the presence of Mycobacterium ulcerans in the environment. FEMS Microbiol Lett 2010, 304:191-194.
19. Durnez L., Stragier P., Roebben K., et al. A comparison of DNA extraction procedures for the detection of Mycobacterium ulcerans, the causative agent of Buruli ulcer, in clinical and environmental specimens. J Microbiol Methods 2008, 76:152-158.
20. Portaels F., Meyers W.M., Ablordey A., et al. First cultivation and characterization of Mycobacterium ulcerans from the environment. PLoS Negl Trop Dis 2008, 2:e178.
21. Tobias N.J., Seemann T., Pidot S.J., et al. Mycolactone gene expression is controlled by strong SigA-like promoters with utility in studies of Mycobacterium ulcerans and Buruli ulcer. PLoS Negl Trop Dis 2009, 3:e553.
22. Demangel C., Stinear T.P., Cole S.T. Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans. Nat Rev Microbiol 2009, 7:50-60.
23. Stragier P., Ablordey A., Bayonne L.M., et al. Heterogeneity among Mycobacterium ulcerans isolates from Africa. Emerg Infect Dis 2006, 12:844-847.
24. Ortiz R.H., Leon D.A., Estevez H.O., et al. Differences in virulence and immune response induced in a murine model by isolates of Mycobacterium ulcerans from different geographic areas. Clin Exp Immunol 2009, 157:271-281.
25. Kaser M., Gutmann O., Hauser J., et al. Lack of insertional-deletional polymorphism in a collection of Mycobacterium ulcerans isolates from Ghanaian Buruli ulcer patients. J Clin Microbiol 2009, 47:3640-3646.
26. Kaser M., Hauser J., Pluschke G. Single nucleotide polymorphisms on the road to strain differentiation in Mycobacterium ulcerans. J Clin Microbiol 2009, 47:3647-3652.
27. Qi W., Kaser M., Roltgen K., et al. Genomic diversity and evolution of Mycobacterium ulcerans revealed by next-generation sequencing. PLoS Pathog 2009, 5:e1000580.
28. Roltgen K., Qi W., Ruf M.T., et al. Single nucleotide polymorphism typing of Mycobacterium ulcerans reveals focal transmission of Buruli ulcer in a highly endemic region of Ghana. PLoS Negl Trop Dis 2010, 4:e751.
29. Boulkroun S., Guenin-Mace L., Thoulouze M.I., et al. Mycolactone suppresses T cell responsiveness by altering both early signaling and posttranslational events. J Immunol 2010, 184:1436-1444.
30. Torrado E., Fraga A.G., Logarinho E., et al. IFN-gamma-dependent activation of macrophages during experimental infections by Mycobacterium ulcerans is impaired by the toxin mycolactone. J Immunol 2010, 184:947-955.
31. Hong H., Coutanceau E., Leclerc M., et al. Mycolactone diffuses from Mycobacterium ulcerans-infected tissues and targets mononuclear cells in peripheral blood and lymphoid organs. PLoS Negl Trop Dis 2008, 2:e325.
32. Phillips R., Sarfo F.S., Guenin-Mace L., et al. Immunosuppressive signature of cutaneous Mycobacterium ulcerans infection in the peripheral blood of patients with Buruli ulcer disease. J Infect Dis 2009, 200:1675-1684.
33. Kiszewski A.E., Becerril E., Aguilar L.D., et al. The local immune response in ulcerative lesions of Buruli disease. Clin Exp Immunol 2006, 143:445-451.
34. Schutte D., Pluschke G. Immunosuppression and treatment-associated inflammatory response in patients with Mycobacterium ulcerans infection (Buruli ulcer). Expert Opin Biol Ther 2009, 9:187-200.
35. Stanford J.L., Revill W.D., Gunthorpe W.J., et al. The production and preliminary investigation of Burulin, a new skin test reagent for Mycobacterium ulcerans infection. J Hyg (Lond) 1975, 74:7-16.
36. Phanzu M.D., Bafende A.E., Imposo B.B., et al. Under-treated necrotizing fasciitis masquerading as ulcerated edematous Mycobacterium ulcerans infection (Buruli ulcer). Am J Trop Med Hyg 2010, 82:478-481.
37. Beissner M., Herbinger K.H., Bretzel G. Laboratory diagnosis of Buruli ulcer disease. Future Microbiol 2010, 5:363-370.
38. Herbinger K.H., Adjei O., Awua-Boateng N.Y., et al. Comparative study of the sensitivity of different diagnostic methods for the laboratory diagnosis of Buruli ulcer disease. Clin Infect Dis 2009, 48:1055-1064.
39. Stragier P., Ablordey A., Durnez L., et al. VNTR analysis differentiates Mycobacterium ulcerans and IS2404 positive mycobacteria. Syst Appl Microbiol 2007, 30:525-530.
40. Sarfo F.S., Phillips R.O., Rangers B., et al. Detection of mycolactone A/B in Mycobacterium ulcerans-infected human tissue. PLoS Negl Trop Dis 2010, 4:e577.
41. O'Brien D.P., Hughes A.J., Cheng A.C., et al. Outcomes for Mycobacterium ulcerans infection with combined surgery and antibiotic therapy: findings from a south-eastern Australian case series. Med J Aust 2007, 186:58-61.
42. Schunk M., Thompson W., Klutse E., et al. Outcome of patients with Buruli ulcer after surgical treatment with or without antimycobacterial treatment in Ghana. Am J Trop Med Hyg 2009, 81:75-81.
43. Junghanss T., Um Boock A., Vogel M., et al. Phase change material for thermotherapy of Buruli ulcer: a prospective observational single centre proof-of-principle trial. PLoS Negl Trop Dis 2009, 3:e380.
44. Etuaful S., Carbonnelle B., Grosset J., et al. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother 2005, 49:3182-3186.
45. World Health Organization Provisional guidance on the role of specific antibiotics in the management of Mycobacterium ulcerans disease (Buruli ulcer) 2004, (WHO/CDS/CPE/GBUI/2004), World Health Organization, Geneva (Switzerland).
46. Chauty A., Ardant M.F., Adeye A., et al. Promising clinical efficacy of streptomycin-rifampin combination for treatment of Buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents Chemother 2007, 51:4029-4035.
47. Sarfo F.S., Phillips R., Asiedu K., et al. The clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease. Antimicrob Agents Chemother 2010, 54:3678-3685.
48. Nienhuis W.A., Stienstra Y., Thompson W.A., et al. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet 2010, 375:664-672.
49. Dossou A.D., Sopoh G.E., Johnson C.R., et al. Management of Mycobacterium ulcerans infection in a pregnant woman in Benin using rifampicin and clarithromycin. Med J Aust 2008, 189:532-533.
50. Ji B., Chauffour A., Robert J., et al. Bactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in mice. Antimicrob Agents Chemother 2008, 52:1912-1916.
51. Kibadi K., Boelaert M., Fraga A.G., et al. Response to treatment in a prospective cohort of patients with large ulcerated lesions suspected to be Buruli ulcer (Mycobacterium ulcerans disease). PLoS Negl Trop Dis 2010, 4:e736.
52. O'Brien D.P., Robson M.E., Callan P.P., et al. "Paradoxical" immune-mediated reactions to Mycobacterium ulcerans during antibiotic treatment: a result of treatment success, not failure. Med J Aust 2009, 191:564-566.